Machowski Michał, Polańska Anna, Gałecka-Nowak Magdalena, Mamzer Aleksandra, Skowrońska Marta, Perzanowska-Brzeszkiewicz Katarzyna, Zając Barbara, Ou-Pokrzewińska Aisha, Pruszczyk Piotr, Kasprzak Jarosław D
Department of Internal Medicine & Cardiology, Medical University of Warsaw, Lindleya 4 St., 02-005 Warsaw, Poland.
I Department of Cardiology, Bieganski Hospital, Medical University of Lodz, Kniaziewicza 1/5 St., 91-347 Lodz, Poland.
J Clin Med. 2022 Jun 9;11(12):3298. doi: 10.3390/jcm11123298.
SARS-CoV-2 infection leads to a hypercoagulable state. The prevalence of pulmonary embolism (PE) seems to be higher in this subgroup of patients.
We combined data from two tertiary referral centers specialized in the management of PE. The aims of this study were as follows: (1) to evaluate the prevalence of PE among a large population of consecutive patients admitted for COVID-19 pneumonia in two centers, (2) to identify a plasma D-dimer threshold that may be useful in PE diagnostic assessment, (3) to characterize the abnormalities associated with PE and mortality in COVID-19 patients.
The incidence of symptomatic acute PE was 19.3%. For diagnosing PE in COVID-19 patients, based on ROC curve analysis, we identified a D-dimer concentration/patient's age ratio of 70, which improved D-dimer diagnostic capacity for PE and led to a reclassification improvement of 14% (NRI 0.14, = 0.03) when compared to a cut-off level of 1000 ng/mL. Especially in severe COVID-19 lung involvement, D-dimer/age ratio cut-off equal to 70 was characterized by high diagnostic feasibility (sensitivity, specificity, negative predictive value, positive predictive value of 83%, 94%, 96%, and 73%, respectively). Apart from PE status, lung involvement and troponin T concentration were also independent predictors of in-hospital mortality. In the subgroup of PE patients, mortality was comparable with non-PE patients (19/88 (21.5%) vs. 101/368 (27.4%) for non-PE, = 0.26) and was associated with older age, higher Bova scores, and higher troponin T concentrations. Age was the sole independent predictor for mortality in this subgroup.
PE in COVID-19 patients is common, but it may not influence mortality when managed at a specialized center. In suspected PE, age-adjusted D-dimer levels (upper limit of normal obtained from the formula patient's age × 70) may still be a useful tool to start the diagnostic workup. In COVID-19 patients without PE, older age, more extensive parenchymal involvement, or higher D-dimer levels are factors predicting mortality.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染会导致高凝状态。在这类患者亚组中,肺栓塞(PE)的患病率似乎更高。
我们合并了两个专门处理PE的三级转诊中心的数据。本研究的目的如下:(1)评估两个中心因新型冠状病毒肺炎(COVID-19)入院的大量连续患者中PE的患病率,(2)确定一个可能有助于PE诊断评估的血浆D-二聚体阈值,(3)描述与COVID-19患者的PE和死亡率相关的异常情况。
有症状的急性PE发生率为19.3%。对于COVID-19患者的PE诊断,基于ROC曲线分析,我们确定D-二聚体浓度与患者年龄的比值为70,这提高了D-二聚体对PE的诊断能力,与1000 ng/mL的临界值相比,重新分类改善率为14%(净重新分类改善值为0.14,P = 0.03)。特别是在COVID-19肺部受累严重的情况下,D-二聚体/年龄比值临界值等于70具有较高的诊断可行性(敏感性、特异性、阴性预测值、阳性预测值分别为83%、94%、96%和73%)。除了PE状态外,肺部受累情况和肌钙蛋白T浓度也是院内死亡的独立预测因素。在PE患者亚组中,死亡率与非PE患者相当(PE患者为19/88(21.5%),非PE患者为101/368(27.4%),P = 0.26),且与年龄较大、Bova评分较高和肌钙蛋白T浓度较高有关。年龄是该亚组中死亡率的唯一独立预测因素。
COVID-19患者中的PE很常见,但在专科中心进行管理时可能不影响死亡率。在疑似PE的情况下,年龄调整后的D-二聚体水平(根据公式患者年龄×70得出的正常上限)可能仍是启动诊断检查的有用工具。在没有PE的COVID-19患者中,年龄较大、实质受累更广泛或D-二聚体水平较高是预测死亡率的因素。